7 Stars, A New Glory of Yangtze in Global Quality Management

Core Viewpoint - Yangtze River Pharmaceutical Group has achieved the "7 stars" Certificate in the category of RbE at the EFQM Sustainable Performance Conference and Global Award Gala 2025, marking a significant advancement in quality management for Chinese pharmaceutical enterprises [1][3]. Group 1: Award Recognition - The "7 Stars" award represents a new height in quality management for Chinese pharmaceutical companies, following the "5 Diamonds" award received in 2021 [1]. - The transition from "5 Diamonds" to "7 Stars" certification occurred within four years, showcasing Yangtze's commitment to excellence [3]. Group 2: Review Process - The certification process involved a rigorous review by a panel of experts from Germany, the UK, and Portugal, which included 30 interviews and 450 Q&As focused on various aspects of the company's operations [3]. - The review highlighted Yangtze's innovative integration of the EFQM model, particularly through the course "EFQM Blooming at Yangtze," which adapts international standards into actionable internal management guidelines [5]. Group 3: Industry Impact - Industry experts view Yangtze's award as a demonstration of the strength of Chinese pharmaceutical brands in global quality management [6]. - The approach taken by Yangtze, characterized by "international standards benchmarking - localized transformation - full-scale implementation," serves as a model for other Chinese enterprises aiming for high-quality development [6].